189 related articles for article (PubMed ID: 37254289)
1. Combination of FAK inhibitor and cytokine-induced killer cell therapy: An alternative therapeutic strategy for patients with triple-negative breast cancer.
Wu CC; Pan MR; Shih SL; Shiau JP; Wu CC; Chang SJ; Kao CN; Chen FM; Hou MF; Luo CW
Biomed Pharmacother; 2023 Jul; 163():114732. PubMed ID: 37254289
[TBL] [Abstract][Full Text] [Related]
2. Impact of FAK Expression on the Cytotoxic Effects of CIK Therapy in Triple-Negative Breast Cancer.
Pan MR; Wu CC; Kan JY; Li QL; Chang SJ; Wu CC; Li CL; Ou-Yang F; Hou MF; Yip HK; Luo CW
Cancers (Basel); 2019 Dec; 12(1):. PubMed ID: 31905966
[TBL] [Abstract][Full Text] [Related]
3. Adoptive cell therapy of triple negative breast cancer with redirected cytokine-induced killer cells.
Sommaggio R; Cappuzzello E; Dalla Pietà A; Tosi A; Palmerini P; Carpanese D; Nicolè L; Rosato A
Oncoimmunology; 2020 Jun; 9(1):1777046. PubMed ID: 32923140
[TBL] [Abstract][Full Text] [Related]
4. Clinical activity of adjuvant cytokine-induced killer cell immunotherapy in patients with post-mastectomy triple-negative breast cancer.
Pan K; Guan XX; Li YQ; Zhao JJ; Li JJ; Qiu HJ; Weng DS; Wang QJ; Liu Q; Huang LX; He J; Chen SP; Ke ML; Zeng YX; Xia JC
Clin Cancer Res; 2014 Jun; 20(11):3003-11. PubMed ID: 24668644
[TBL] [Abstract][Full Text] [Related]
5. Adjuvant alternative cytokine-induced killer cell combined with natural killer cell immunotherapy improves the prognosis of post-mastectomy breast cancer.
Yang X; Weng D; Pan Q; Xiang T; Yang C; Wu Z; Li M; Xie S; Tang Y; Xia J; Zhao J
Front Immunol; 2022; 13():974487. PubMed ID: 36439119
[TBL] [Abstract][Full Text] [Related]
6. A chalcone-syringaldehyde hybrid inhibits triple-negative breast cancer cell proliferation and migration by inhibiting CKAP2-mediated FAK and STAT3 phosphorylation.
Jin XX; Mei YN; Shen Z; Zhu JF; Xing SH; Yang HM; Liang G; Zheng XH
Phytomedicine; 2022 Jul; 101():154087. PubMed ID: 35429924
[TBL] [Abstract][Full Text] [Related]
7. Targeting the crosstalk between cytokine-induced killer cells and myeloid-derived suppressor cells in hepatocellular carcinoma.
Yu SJ; Ma C; Heinrich B; Brown ZJ; Sandhu M; Zhang Q; Fu Q; Agdashian D; Rosato U; Korangy F; Greten TF
J Hepatol; 2019 Mar; 70(3):449-457. PubMed ID: 30414862
[TBL] [Abstract][Full Text] [Related]
8. Focal adhesion kinase (FAK) activation by estrogens involves GPER in triple-negative breast cancer cells.
Rigiracciolo DC; Santolla MF; Lappano R; Vivacqua A; Cirillo F; Galli GR; Talia M; Muglia L; Pellegrino M; Nohata N; Di Martino MT; Maggiolini M
J Exp Clin Cancer Res; 2019 Feb; 38(1):58. PubMed ID: 30728047
[TBL] [Abstract][Full Text] [Related]
9. Combining antiangiogenic therapy with adoptive cell immunotherapy exerts better antitumor effects in non-small cell lung cancer models.
Shi S; Wang R; Chen Y; Song H; Chen L; Huang G
PLoS One; 2013; 8(6):e65757. PubMed ID: 23799045
[TBL] [Abstract][Full Text] [Related]
10. Effects of two different immunotherapies on triple negative breast cancer in animal model.
Liu X; Hu J; Cao W; Qu H; Wang Y; Ma Z; Li F
Cell Immunol; 2013; 284(1-2):111-8. PubMed ID: 23973874
[TBL] [Abstract][Full Text] [Related]
11. COL8A1 facilitates the growth of triple-negative breast cancer via FAK/Src activation.
Sato F; Sagara A; Tajima K; Miura S; Inaba K; Ando Y; Oku T; Murakami T; Kato Y; Yumoto T
Breast Cancer Res Treat; 2022 Jul; 194(2):243-256. PubMed ID: 35624176
[TBL] [Abstract][Full Text] [Related]
12. Effectiveness and safety of chemotherapy combined with cytokine-induced killer cell /dendritic cell-cytokine-induced killer cell therapy for treatment of gastric cancer in China: A systematic review and meta-analysis.
Mu Y; Zhou CH; Chen SF; Ding J; Zhang YX; Yang YP; Wang WH
Cytotherapy; 2016 Sep; 18(9):1162-77. PubMed ID: 27421742
[TBL] [Abstract][Full Text] [Related]
13. Bevacizumab improves the antitumor efficacy of adoptive cytokine-induced killer cells therapy in non-small cell lung cancer models.
Tao L; Huang G; Shi S; Chen L
Med Oncol; 2014 Jan; 31(1):777. PubMed ID: 24271420
[TBL] [Abstract][Full Text] [Related]
14. Capecitabine metronomic chemotherapy combined with autologous CIK cell immunotherapy in the treatment of recurrent and metastatic triple-negative breast cancer.
Chen S; Yang Y; Jiao Y; Sun H; Yan Z
J BUON; 2021; 26(3):734-740. PubMed ID: 34268928
[TBL] [Abstract][Full Text] [Related]
15. FAK activation is required for IGF1R-mediated regulation of EMT, migration, and invasion in mesenchymal triple negative breast cancer cells.
Taliaferro-Smith L; Oberlick E; Liu T; McGlothen T; Alcaide T; Tobin R; Donnelly S; Commander R; Kline E; Nagaraju GP; Havel L; Marcus A; Nahta R; O'Regan R
Oncotarget; 2015 Mar; 6(7):4757-72. PubMed ID: 25749031
[TBL] [Abstract][Full Text] [Related]
16. Adjuvant treatment for triple-negative breast cancer: a retrospective study of immunotherapy with autologous cytokine-induced killer cells in 294 patients.
Zhang Y; Wang S; Yang B; Lu S; Du Y; Liu H
Cancer Biol Med; 2019 May; 16(2):350-360. PubMed ID: 31516755
[TBL] [Abstract][Full Text] [Related]
17. BRD4 modulates vulnerability of triple-negative breast cancer to targeting of integrin-dependent signaling pathways.
Zhang Y; Xu B; Shi J; Li J; Lu X; Xu L; Yang H; Hamad N; Wang C; Napier D; He S; Liu C; Liu Z; Qian H; Chen L; Wei X; Zheng X; Huang JA; Thibault O; Craven R; Wei D; Pan Y; Zhou BP; Wu Y; Yang XH
Cell Oncol (Dordr); 2020 Dec; 43(6):1049-1066. PubMed ID: 33006750
[TBL] [Abstract][Full Text] [Related]
18. Synergistic antitumor effect of combining metronomic chemotherapy with adoptive cell immunotherapy in nude mice.
Shi S; Tao L; Song H; Chen L; Huang G
APMIS; 2014 May; 122(5):380-91. PubMed ID: 24628659
[TBL] [Abstract][Full Text] [Related]
19. Atezolizumab potentiates Tcell-mediated cytotoxicity and coordinates with FAK to suppress cell invasion and motility in PD-L1
Mohan N; Hosain S; Zhao J; Shen Y; Luo X; Jiang J; Endo Y; Wu WJ
Oncoimmunology; 2019; 8(9):e1624128. PubMed ID: 31428520
[TBL] [Abstract][Full Text] [Related]
20. Immunotherapy for triple-negative breast cancer: Existing challenges and exciting prospects.
Jia H; Truica CI; Wang B; Wang Y; Ren X; Harvey HA; Song J; Yang JM
Drug Resist Updat; 2017 May; 32():1-15. PubMed ID: 29145974
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]